Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.

Backed by the Economic Development Board (EDB), the hub was launched on Nov 14 at the Lilly Digital Health and Lilly Centre ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 519.47% and ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

Conditions are getting a bit more challenging for the drugmaker.

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Even with this partial rebound, Lilly's share price remains roughly 13% below the peak set in late August. Some investors ...

Eli Lilly (NYSE:LLY) shares were on track to snap six straight sessions of losses on Thursday, as the stock rose 1.9% at $790 ...